GT Biopharma, Inc.
GTBP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000109657
No open-market purchases or sales by GT Biopharma, Inc. insiders were filed in the last 90 days; 59 institutions reported holding it in 13F filings for Q2 2026, worth $1.02M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by GT Biopharma, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for GT Biopharma, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Casamento Charles J | Director | – | Sep 8, 2025 | 0 |
| Urban Alan Louis | Chief Financial Officer | – | Sep 8, 2025 | 0 |
| Breen Michael Martin | CEO and Director | 856,218 | Sep 8, 2025 | 0 |
| Kramer Hilary | Director | – | Sep 8, 2025 | 0 |
| Mun-Gavin David C. | Director | – | Sep 8, 2025 | 0 |
| Ohri Manu | CFO & Secretary | 300,000Indirect | Aug 15, 2023 | 0 |
| Shrotriya Rajesh C MD | Director | – | Feb 1, 2023 | 0 |
| Wendel Bruce | Director | 352,655 | Feb 1, 2023 | 0 |
| Berk Gregory | Pres. of R&D, CMO | 278,058 | Jul 19, 2022 | 0 |
| Choy Gavin | Acting Chief Financial Officer | – | Feb 14, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 11, 2023 (view filing) | Apr 11 | Same day | Breen Michael MartinExecutive Chairman/Interim CEO | PPurchase | +50.0K | $0.50 | +$25.0K | +8.2%656.2K after | |
| Apr 10, 2023 (view filing) | Apr 6 | 4 days | Ohri ManuCFO & Secretary | PPurchase | +50.0K | $0.50 | +$25.0K | New position50.0K after | |
| Oct 7, 2021 (view filing) | Nov 16-Dec 22, 2020 | 325 daysLate | Wendel BruceDirector | PPurchase | +5.08K | $5.17 | +$26.3K | New position5.08K after | 3 lots |